Valuation: PTC Therapeutics, Inc.

Market Cap 6.5B 5.7B 5.29B 4.86B 9.16B 628B 9.29B 63.02B 24.66B 307B 24.41B 23.89B 1,061B P/E 2026 *
114x
P/E 2027 * 30.2x
Enterprise Value 4.64B 4.07B 3.78B 3.47B 6.54B 448B 6.64B 44.99B 17.61B 219B 17.43B 17.05B 757B EV / Sales 2026 *
3.93x
EV / Sales 2027 * 3.64x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -
1 day-0.13%
1 week-0.56%
Current month-3.89%
1 month-3.16%
3 months+10.66%
6 months+2.93%
Current year+3.21%
1 week 77.22
Extreme 77.22
80.56
1 month 76.55
Extreme 76.55
90.87
Current year 61.43
Extreme 61.43
90.87
1 year 43.18
Extreme 43.175
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 2023-03-21
Director of Finance/CFO 41 2023-07-12
Chief Tech/Sci/R&D Officer - 2017-09-30
Director TitleAgeSince
Chairman 74 2004-10-31
Chairman 80 1998-03-30
Director/Board Member 65 2005-11-30
Date Insider Type Main position Quantity % Market Cap.
7/14/26 Sell

Chief Financial Officer

-3,494 0.0042%
7/9/26 Fiscal year

Chief Technology Officer

7,392 0.0089%
7/9/26 Fiscal year

Director

47,502 0.0573%
Change 5-day change 1-year change 3-year change Capi.($)
-0.13%-0.56%+69.00%+98.38% 6.5B
-1.05%+0.55%+49.79%+151.71% 1,037B
+2.00%+3.49%+52.22%+50.20% 615B
-1.09%+3.76%+35.37%+76.22% 448B
+3.31%+3.32%+31.11%+25.27% 326B
-0.40%+1.35%+34.15%+37.58% 293B
-0.68%-0.10%+18.19%+17.03% 264B
-2.46%-7.18%-29.61%-43.33% 216B
-0.05%+2.16%+19.75%+55.89% 198B
+0.05%-1.03%+18.31%+61.63% 162B
Average +0.01%+0.95%+29.83%+53.06% 356.39B
Weighted average by Cap. +0.38%+1.47%+35.20%+72.50%

Financials

2026 *2027 *
Net sales 1.18B 1.04B 962M 884M 1.67B 114B 1.69B 11.46B 4.49B 55.84B 4.44B 4.34B 193B 1.34B 1.18B 1.09B 1B 1.89B 130B 1.92B 13.02B 5.1B 63.45B 5.04B 4.94B 219B
Net income 45.92M 40.24M 37.36M 34.33M 64.68M 4.43B 65.63M 445M 174M 2.17B 172M 169M 7.49B 195M 170M 158M 145M 274M 18.77B 278M 1.89B 738M 9.19B 730M 715M 31.74B
Net Debt -1.86B -1.63B -1.51B -1.39B -2.62B -180B -2.66B -18.03B -7.06B -87.86B -6.99B -6.83B -304B -1.61B -1.41B -1.31B -1.2B -2.27B -155B -2.3B -15.61B -6.11B -76.05B -6.05B -5.92B -263B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
26-07-22 US$78.40 -0.13% 583,883
26-07-21 US$78.50 +0.63% 1,145,977
26-07-20 US$78.01 -0.74% 954,314
26-07-17 US$78.59 +0.09% 704,130
26-07-16 US$78.52 -0.41% 1,888,995
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
78.40USD
Average target price
96.07USD
Spread / Average Target
+22.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock